Leerink starts Verona at buy

Leerink starts Verona at buy

Leerink launched coverage of Verona Pharma (NADAQ:VRNA; AIM:VRP) with a “buy” rating and $22 price target after its recent cross-listing from the London Stock Exchange to NASDAQ. The stock closed at $13.52 on May 19.

Read More

BMJ article dovetails with Ortho RTi focus

BMJ article dovetails with Ortho RTi focus

An article in the latest issue of the weekly peer-reviewed journal, The BMJ, about arthroscopic surgery for degenerative knee arthritis and meniscal tears appears to dovetail with an approach by Ortho Regenerative Technologies and its biologic scaffold for soft tissue injuries.

Read More

John Hopkins researchers discuss Titan’s Probuphine

John Hopkins researchers discuss Titan’s Probuphine

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine was featured in an article about new developments in managing opioid addiction that was published in the peer-reviewed journal, Drug, Design, Development and Therapy. 

Read More

Norgine to acquire Merus Labs

Norgine to acquire Merus Labs

Norgine, a European specialist pharmaceutical company, has agreed to acquire Merus Labs International (NASDAQ:MSLI; TSX:MSL) for $1.65 a share in cash, including the assumption of debt obligations, for a total enterprise value of about $342-million.

Read More

Maxim cuts Stellar Bio price target to $2

Maxim cuts Stellar Bio price target to $2

Maxim Group slashed its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $2 from $4, but maintained its “buy” rating, after the company reported fiscal second quarter results. The stock closed at $1.32 on May 9.

Read More

Analysts starts Tocagen at buy, MP

Analysts starts Tocagen at buy, MP

Analysts at Stifel and Leerink initiated coverage of Tocagen (NASDAQ:TOCA) with “buy” and “market perform” ratings, and price targets of $24 and $19, respectively. The stock closed at $17.40 on May 5.

Read More

Histogenics pathway for NeoCart cleared in Japan

Histogenics pathway for NeoCart cleared in Japan

Histogenics (NASDAQ:HSGX) has successfully completed all formal consultations with the Office of Cellular and Tissue-based Products of the Japan Pharmaceuticals and Medical Devices Agency (PMDA) regarding the marketing and manufacturing authorization pathway for its NeoCart autologous cell therapy to treat cartilage defects in the knee in the Japanese market. 

Read More

Theratechnologies partner files ibalizumab BLA

Theratechnologies partner files ibalizumab BLA

Theratechnologies’ (TSX:TH) partner, TaiMed Biologics of Taiwan, completed the submission of a biologics license application (BLA) to the FDA for ibalizumab for the treatment of multidrug-resistant human immunodeficiency virus-1 (MDR HIV-1).

Read More